Research Center: TrialsWest
Location: 6 Barrington Street, Spearwood in Perth, WA, Australia
Lead Researcher: Professor Peter Bremner
HREC Committee: This study has been reviewed and approved by the Bellberry Human Research Ethics Committee

Background

Chronic Obstructive Pulmonary Disorder (COPD) is one of the common diseases worldwide. Current treatments for COPD have had an inadequate effect on symptoms, lung function, exacerbation, and long-term disease progression. Researchers are focusing on developing new effective treatments for COPD, aiming to benefit those suffering from it.

This study involves a potential new treatment for COPD. This purpose of this study is to investigate the effectiveness of a potential COPD treatment (Dupilumab) on lung function, exacerbation and quality of life among those with COPD. Dupilumab is a medication approved by the Australian federal government to treat moderate-to-severe atopic dermatitis and moderate-to-severe asthma with Type 2 inflammation.

The study seeks adults aged 40 to 80 years old who are diagnosed with moderate to severe COPD. Participants must comply with the study requirements for over approximately 69 weeks (about 16 months). 

Why Participate? 

• You may receive a potential treatment that may provide improvements and help manage your COPD symptoms.
• You may provide valuable information that may help others with COPD in the future.
• You will be reimbursed for any study-related travel expenses incurred.
• You will be helping to advance medical research.

Your Rights

• If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.
• Your records relating to this study and any other information received will be kept strictly confidential, except as required by the law.
• Qualified health professionals will monitor your health as it relates to the study.

Who Can Participate?

• Men and women aged 40 to 80 years old who are diagnosed with moderate to severe COPD.
• Able to attend 19 study visits (about 2-4 hours per visit) as well as comply with the following study requirements at the research site over approximately 69 weeks (About 16 months).
  • The potential treatment is to be administered through an injection. Participants must be willing to take the potential treatment via an injection.
  • Must be willing to complete eDiary entries

About The Research Center:

TrialsWest 

Western Respiratory Trial Specialists (WRTS) was established in December 2012. In June 2018, we changed our name to TrialsWest to reflect the fact that we are now involved in research in therapeutics areas other than respiratory.

We have been involved in numerous phase II to IV clinical trials sponsored by the leading global pharmaceutical companies including GlaxoSmithKline (GSK), AstraZeneca, Novartis, Merck, Sanofi Aventis, Boehringer Ingelheim, Bayer, Pearl Therapeutics and Biogen.